Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.
Suneel D KamathAparna KalyanSheetal KircherHalla NimeiriAngela J FoughtAl BensonMary MulcahyPublished in: The oncologist (2019)
Gemcitabine and ipilimumab is a safe and feasible regimen for treating advanced pancreatic cancer. Although one patient in this study had a relatively durable response of nearly 20 months, adding ipilimumab to gemcitabine does not appear to be more effective than gemcitabine alone in advanced pancreatic cancer.